The Chair of UK’s Health and Social Care Select Committee, MP Jeremy Hunt, stated in Parliament that Israel shows that a booster program reduces Covid hospitalizations in just two weeks. Israeli research also shows that the booster gives 10 times more antibodies than the second jab.
Very Good news. Surgeons at Israel’s Soroka hospital used Israeli technology to separate the heads and major blood vessels of two conjoined Israeli baby girls, assisted by a UK Muslim specialist. The babies were visibly delighted to be able to see each other for the first time.
The U.S.’s largest life insurer company New York Life has partnered Israel’s Empathy (see previously) The Israeli app will help guide NYL customers navigate the complexities experienced with loss by offering logistics and emotional support.
Israel’s Eleos Health has developed an AI-powered voice analysis system to help behavioral health clinicians and care teams provide better personalized, care to mental health patients and reduce staff burnout. It is deployed at Solvista Health, Achieve, Yeshiva University and ReachLink.
Tel Aviv University scientists have discovered more on the effects of Hyperbaric Oxygen Therapy (HBOT – see ). It significantly improved vascular function and blood flow to the brain, plus reduced and removed the build-up of amyloid plaque on the brain – a common symptom of Alzheimer’s.
Israel’s SpliSense (see previously) uses mRNA to fix the root cause of cystic fibrosis - genetic mutations that create a non-functioning protein (CFTR). It not only treats patients with no current treatment but is also much cheaper than existing treatments.
Recent studies show that the metabolite succinate, secreted by gut bacteria, can cause Inflammatory Bowel Disease (IBD). Scientists at Israel’s Ben Gurion University and in South Korea have developed therapeutic peptides to remove succinates from the body. Patents have been filed.
Researchers at Tel Aviv University have discovered that a type of white blood cell (eosinophils) can be utilized to fight cancer. They have a double effect, producing destructive proteins, while at the same time summoning the immune system’s cancer-fighting T-cells.
More details on the breakthrough technology of Israel’s Nectin (see previously). Monoclonal antibodies, with toxins attached, are sent directly to the cancer cell to break its ability to immobilize the body’s immune system. Clinical trials are expected to start in early 2022.
Researchers at Israel’s Weizmann Institute have developed a small molecule that stops the coronavirus spike protein from attaching to the lungs’ ACE2 receptor. But it doesn’t damage ACE2’s normal function. (See also for similarities with opaganib from Israel’s Redhill).